Menu

Top Stories

Published on Monday, August 19, 2019

Update: CSL Behring announcement on their product Zemaira

Update: CSL Behring announcement on their product Zemaira

The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1):

"CSL Behring is pleased to inform you that we are lifting our precautionary distribution hold, and ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)] is now available for our customers.

"With this release of ZEMAIRA, CSL Behring is introducing a new and improved reconstitution device called the Mix2Vial® Transfer Set.

"The Mix2Vial Transfer Set, designed for use with ZEMAIRA, improves reconstitution and streamlines Alpha-1 therapy by:

  • Helps prevent vacuum loss
  • Less frequent spillage
  • Guided technique leading to safer handling

"Important Note: If the product comes with the Mix2Vial Transfer Set, you must only use the Mix2Vial and never use the old spike.

If you are a patient who typically self-infuses, please consult your healthcare professional."


Print

White House prepares to ban flavored e-cigs

Tuesday, September 17, 2019
The Trump administration said it is planning to ban all e-cigarette flavors following a recent nationwide outbreak of severe lung illnesses linked to vaping and five reported deaths, according to pool reports. President Donald Trump told...
Divider

Breaking a 10-year streak, the number of uninsured Americans rises

Friday, September 13, 2019
For the first time in a decade, the number of Americans without health insurance has risen — by about 2 million people in 2018 — according to the annual U.S. Census Bureau report. The Census found that 8.5% of the U.S. population...
Divider

House Speaker Nancy Pelosi to release drug pricing plan after Congress returns

Thursday, September 12, 2019
As published on the National Health Council Insider and other news outlets, House Speaker Nancy Pelosi will release a drug-pricing plan shortly after Congress returns to work after its August recess, a House Democratic aide confirmed. Democrats...
Divider

Study analyzes the degree of concordance among international guidelines regarding Alpha-1 Antitrypsin Deficiency

Thursday, September 12, 2019
The International Journal of Chronic Obstructive Pulmonary Disease recently published the outcomes of a study entitled “An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency,”...
Divider

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

Thursday, September 12, 2019
The American Journal of Respiratory and Critical Care Medicine, of the American Thoracic Society (ATS), recently published an article about the outcomes of a clinical trial entitled: “Effect of Double Dose of Alpha 1-antitrypsin Augmentation...
Divider

News and updates from the U.S. COPD Coalition

Wednesday, September 11, 2019
The U.S. COPD Coalition (USCC), which the Alpha-1 Foundation is a member of, has remained engaged in issues confronting our communities and continued its collaboration with other groups to positively impact access to diagnosis, treatment, and...
Divider

FDA and NIH public workshop: Agenda now available

Wednesday, September 4, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled “Developing Therapeutics for Alpha-1 Antitrypsin Deficiency,” at the Natcher Conference Center, Building 45...
Divider

Update: CSL Behring announcement on their product Zemaira

Monday, August 19, 2019
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): "CSL Behring is...
Divider

DNA data shared in ways patients may find surprising

Tuesday, August 13, 2019
Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to...
Divider

Arrowhead Pharmaceuticals doses first patient in SEQUOIA Phase 2/3 Study of ARO-AAT for treatment of Alpha-1 liver disease

Thursday, August 8, 2019
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference...
Divider

CSL Behring announcement on their product Zemaira

Tuesday, August 6, 2019
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “CSL Behring...
Divider

The 28th Annual Alpha-1 National Conference: The Alpha of Tomorrow

Tuesday, July 23, 2019
Orlando, Florida was the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community in the world, as the Alpha-1 Foundation held its 28th Annual Alpha-1 National...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive